SCHEMBL6020147

SCHEMBL6020147

COC(=O)c1sc2cc(OC)c(OC)cc2c1CCC1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
STING1 Q86WV6 2/20 0.43
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
ACHE P22303 5/20 0.38
MAPT P10636 3/20 0.38
TSHR P16473 1/20 0.38
PIK3CD O00329 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
UHRF1 Q96T88 1/20 0.35
MAPK1 P28482 2/20 0.35
LMNA P02545 1/20 0.35
GLA P06280 2/20 0.34
HPGD P15428 2/20 0.34
ALOX15 P16050 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CASP3 P42574 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6020724 0.89 STING1 (0.46) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL31564753 0.79 L3MBTL1 (0.49) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL6021442 0.79 STING1 (0.46) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL5214310 0.73 L3MBTL1 (0.53) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL31564755 0.73 L3MBTL1 (0.53) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL1609028 0.73 STING1 (0.63) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL11794822 0.73 L3MBTL1 (0.53) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL6020606 0.72 STING1 (0.44) L3MBTL1STING1ACHEHPGD
SCHEMBL31564821 0.72 L3MBTL1 (0.52) L3MBTL1STING1KDM4EALDH1A1HSD17B10
SCHEMBL31564676 0.72 KDM4E (0.59) L3MBTL1STING1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636210-A1 CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS Warner-Lambert Company LLC (US) 2006-03-22 EP disclosed
US-20050020630-A1 Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents CONNOLLY MICHAEL KEVIN (US) 2005-01-27 US disclosed
WO-2004108713-A1 CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020630-A1 Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents MALT1, CYP1B1, WEE2 L3MBTL1 382/4885STING1 2586/4885KDM4E 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.